Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 20/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16898774 | 0.99 | IRAK4 (0.52) | IRAK4KCNH2 | |
| Hypochlorous Acid SCHEMBL20787488 | 0.99 | IRAK4 (0.52) | IRAK4KCNH2 | |
| SCHEMBL18392027 | 0.90 | IRAK4 (0.65) | IRAK4KCNH2 | |
| SCHEMBL16898757 | 0.88 | IRAK4 (0.58) | IRAK4KCNH2 | |
| SCHEMBL16899061 | 0.85 | IRAK4 (0.65) | IRAK4 | |
| SCHEMBL18391964 | 0.84 | IRAK4 (0.62) | IRAK4KCNH2 | |
| SCHEMBL16898791 | 0.84 | IRAK4 (0.46) | IRAK4KCNH2 | |
| Hydrochloric Acid SCHEMBL16899260 | 0.84 | IRAK4 (0.64) | IRAK4 | |
| Hydrochloric Acid SCHEMBL22437270 | 0.84 | IRAK4 (0.46) | IRAK4KCNH2 | |
| Hydrochloric Acid SCHEMBL20377753 | 0.84 | IRAK4 (0.61) | IRAK4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200345704-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | CURIS, INC. | 2020-11-05 | — | — | US | disclosed |
| EP-3092226-B1 | INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2019-03-13 | — | — | EP | disclosed |
| US-20160326151-A1 | Indazole Compounds as IRAK4 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-11-10 | — | — | US | disclosed |
| US-20160326151-A1 | Indazole Compounds as IRAK4 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-11-10 | — | — | US | disclosed |
| WO-2015104662-A1 | INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345704-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | IRAK4, IRAK2, JAK2 | IRAK4 1/4885KCNH2 1944/4885 |
| US-20160326151-A1 | Indazole Compounds as IRAK4 Inhibitors | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885KCNH2 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.